The Antifolates

Michele Visentin, Rongbao Zhao, I. David Goldman

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.

Original languageEnglish (US)
Pages (from-to)629-648
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume26
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Folic Acid Antagonists
Folic Acid
Methotrexate
Pharmacology
Drug Therapy
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antifolates
  • Folate receptor-mediated endocytosis
  • Folate receptors
  • Methotrexate
  • Pemetrexed
  • Pralatrexate
  • Proton-coupled folate transporter (PCFT)
  • Reduced folate carrier (RFC)

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

The Antifolates. / Visentin, Michele; Zhao, Rongbao; Goldman, I. David.

In: Hematology/Oncology Clinics of North America, Vol. 26, No. 3, 06.2012, p. 629-648.

Research output: Contribution to journalArticle

Visentin, Michele ; Zhao, Rongbao ; Goldman, I. David. / The Antifolates. In: Hematology/Oncology Clinics of North America. 2012 ; Vol. 26, No. 3. pp. 629-648.
@article{98105e1c81254f6da9d02af889f34915,
title = "The Antifolates",
abstract = "This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.",
keywords = "Antifolates, Folate receptor-mediated endocytosis, Folate receptors, Methotrexate, Pemetrexed, Pralatrexate, Proton-coupled folate transporter (PCFT), Reduced folate carrier (RFC)",
author = "Michele Visentin and Rongbao Zhao and Goldman, {I. David}",
year = "2012",
month = "6",
doi = "10.1016/j.hoc.2012.02.002",
language = "English (US)",
volume = "26",
pages = "629--648",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The Antifolates

AU - Visentin, Michele

AU - Zhao, Rongbao

AU - Goldman, I. David

PY - 2012/6

Y1 - 2012/6

N2 - This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.

AB - This article focuses on the cellular, biochemical, and molecular pharmacology of antifolates and how a basic understanding of the mechanism of action of methotrexate, its cytotoxic determinants, mechanisms of resistance, and transport into and out of cells has led to the development of a new generation of antifolates, a process that continues in the laboratory and in the clinics. New approaches to folate-based cancer chemotherapy are described based on the targeted delivery of drugs to malignant cells.

KW - Antifolates

KW - Folate receptor-mediated endocytosis

KW - Folate receptors

KW - Methotrexate

KW - Pemetrexed

KW - Pralatrexate

KW - Proton-coupled folate transporter (PCFT)

KW - Reduced folate carrier (RFC)

UR - http://www.scopus.com/inward/record.url?scp=84859955788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859955788&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2012.02.002

DO - 10.1016/j.hoc.2012.02.002

M3 - Article

C2 - 22520983

AN - SCOPUS:84859955788

VL - 26

SP - 629

EP - 648

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 3

ER -